Seeking Alpha

Shares of BioCryst Pharmaceuticals (BCRX -30%) react hard to yesterday's announcement, hitting...

Shares of BioCryst Pharmaceuticals (BCRX -30%) react hard to yesterday's announcement, hitting new 52-week lows after the drug-maker withdrew its Investigational New Drug application for its antiviral nucleoside treatment for hepatitis C, BCX5191. The FDA has raised concerns related to the drug's preclinical toxicity profile at levels necessary for it to be effective.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|